Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks

Recruiting now

Conditions studied: Lung Cancer

In brief

Low-dose CT (LDCT) screening for lung cancer (LCS) has been shown to reduce lung cancer specific mortality in multiple randomised controlled trials. However, although LDCT screening has been demonstrated to reduce cancer- specific mortality, there remain outstanding questions regarding how screening can be implemented. In particular, indeterminate nodules are common, and can be challenging to distinguish from benign nodules on CT appearances alone. Furthermore, distinguishing cancers which are likely to become clinically significant from those that will remain indolent is challenging, but essential to prevent over-treatment and overdiagnosis. There is significant interest in using a multi-modal approach to LCS, incorporating biomarkers obtained from minimally-invasive samples alongside LDCT to improve ability to recognise clinically-significant lung cancers at an early stage. The Targeted Lung Health Check (TLHC) programme is an NHS programme with the aim of using LDCT screening in appropriately high-risk individuals to improve early diagnosis and survival in lung cancer. The North Central London TLHC programme started in December 2022. The purpose of the ALPINE study is to develop a platform to allow collection of minimally-invasive samples from participants undergoing screening within the North Central London TLHC programme. The use of such biomarkers in the diagnosis of lung cancer is a rapidly developing field and novel techniques and technologies are continuously under development. The ALPINE study will generate a cohort with matched biosamples, CT scans and clinical data which will be uniquely well placed to serve to develop or validate biomarkers in lung cancer screening and risk prediction.

Key facts

Study ID

NCT05902559

Run by

University College, London

People needed

10000

Starts

2023-08-01

Expected to finish

2028-11-20

Last updated by the study team

2024-10-15

Who can join

Age: 55 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Attended one of more visits as part of the NCL NHS TLHC programme
• Adults aged between 55 years and 74 years and 364 days
• Have capacity and can provide written consent

You may not qualify if…

• Declines participation in ALPINE
• Lacking capacity and unable to provide written consent
• Patients who are considered by the clinician to be unfit/not suitable for enrolment in ALPINE

Where it is running

• University College London Hospitals NHS Foundation Trust — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.